Targeted Radionuclide Therapy: A Historical and Personal Review.

Area of Science:

• Nuclear Medicine and Oncology
• Radiopharmaceutical development
• Theranostics

Background:

• The historical development of targeted radionuclide therapy (TRT), often termed the 'Magic Bullet', is traced from the discovery of natural and artificial radioactivity.
• Early applications utilized radioiodine for thyroid conditions, leading to its use in treating differentiated thyroid carcinoma due to observed antitumor effects.

Observation:

• The 'Magic Bullet' concept has expanded to include radioiodinated meta-iodobenzylguanidine (131I-MIBG) for pheochromocytomas and radioiodinated anti-CD20 IgG for non-Hodgkin's lymphoma.
• Beta-emitting radionuclides like Yttrium-90 (90Y) and Lutetium-177 (177Lu) have been introduced, with 177Lu increasingly favored over 90Y for neuroendocrine tumors due to physical properties.
• Targeted therapies for prostate cancer are advancing, including agents targeting prostate-specific membrane antigen (PSMA) and bone-seeking radiometals for pain relief in metastatic disease.

Findings:

• The evolution includes the development of targeted radionuclide therapeutics for prostate cancer, utilizing both antibody-based and small-molecule approaches against PSMA.
• Radiometals targeting bone hydroxyapatite are used to palliate pain from bone metastases, particularly in prostate cancer.
• Radium-223 (223Ra), an alpha emitter, represents a recent advancement, offering targeted radiation for bone metastases with enhanced safety due to its limited range.

Implications:

• Targeted radionuclide therapy continues to evolve, with ongoing evaluation of alpha-emitting radiometals as alternatives to beta emitters for labeling targeting molecules.
• The expansion of TRT demonstrates a growing arsenal for treating various cancers, including rare tumors and metastatic disease.
• Future directions involve refining radiometal selection and targeting vectors to optimize therapeutic efficacy and patient safety across a broader spectrum of malignancies.